论文部分内容阅读
骨髓移植(BMT)的预处理方案——大剂量马利兰(BU)和环磷酰胺(CY)联用,不行全身放疗,据报道可减少并发症且不降低抗白血病作用。作者为此研究了一组15例异基因 BMT(Allo-BMT)和1例自体 BMT(A-BMT)病例。患者服用 BU 每次1mg/kg,一日4次,连用4天,总量16mg/kg,静注CY60mg/kg,连用2天。给予剂量接近理想体重剂量。理想体重根据日本标准体重测量法计算,即:(身高[cm]—100)×0.9kg.末剂 CY 后第二天输入骨髓细胞。BMT 后给予重组人类粒细胞集落刺激因
Bone marrow transplantation (BMT) pre-treatment program - high-dose combination of marilan (BU) and cyclophosphamide (CY), without systemic radiotherapy, has been reported to reduce complications and does not reduce the anti-leukemia effect. To this end, the authors studied a group of 15 allogeneic BMT (Allo-BMT) and 1 autologous BMT (A-BMT) cases. Patients taking BU 1mg / kg each time, 4 times a day, once every 4 days, the total 16mg / kg, intravenous CY60mg / kg, once every 2 days. The dose is given near ideal body weight. The ideal body weight was calculated according to the Japanese standard body weight measurement, namely: (height [cm] -100) × 0.9 kg. Bone marrow cells were input the next day after the last dose CY. After administration of recombinant human granulocyte colony stimulating factor